) and AC Immune, Ltd. (Lausanne,  Switzerland, 

), a Swiss  Biotech company developing therapies against Alzheimer’s disease, have entered  into an exclusive global license agreement and research collaboration for the  development of anti-beta-amyloid antibodies for the potential treatment of  Alzheimer’s disease and other human diseases. 

Under the terms of this agreement, Genentech will make an  upfront payment to AC Immune, with the potential for a total of over $300  million in payments upon successful completion of clinical and regulatory  milestones for Alzheimer’s and additional applications. 

Upon commercialization of a product, Genentech will pay AC  Immune royalties on net sales of AC Immune’s antibodies. Genentech will provide  funding for a multi-year collaborative research program and it will also cover  all development and clinical costs of the lead antibody and subsequent antibody  candidates.

News

Genentech, Inc. (San Francisco, CA, www.genentech.com) and AC Immune, Ltd. (Lausanne, Switzerland, www.acimmune.com), a Swiss Biotech company developing therapies against Alzheimer's disease, have entered into an exclusive global license agreement and research collaboration for the development of anti-beta-amyloid antibodies for the potential treatment of Alzheimer's disease and other human diseases.